ABSTRACT
Introduction Lumbar intervertebral disc degeneration (DD) disease is one of the main risk factors for low back pain. The social and economic importance of low back pain is very high: back pain is among the leading causes of absenteeism and the cost of treating back pain exceeds the cost of treatment of many other serious diseases (cancer, in particular); however, therapy does not always provide the desired result. Despite the variability of biological studies of lumbar DD, it is still not fully understood, partially due to the fact that there are only few studies using systematic and integrative approaches. Hence, more integrative omics studies are needed to link all pieces of knowledge together, build a complete picture of biology of lumbar DD and obtain a deeper understanding of the processes underlying this pathology.
Methods and analysis This disease-oriented biobank to study lumbar disc degeneration will be recruited from two clinical centers. A total of 1100 participants with available lumbar MRI will be enrolled during the three-year period. General information about a patient, medical history, lumbar MRI parameters and biological material (whole blood and plasma) will be collected in the centers at baseline. Then, from those patients, who will undergo a spine surgery during the treatment, disc tissue samples will be gained. Eventually, postoperative clinical data will be collected from operated patients during the follow-up.
Ethics and dissemination The study will be performed according to the Helsinki Declaration. The study protocol was approved by the Local Ethical Committee of NRITO (№034/20 dated 02 Oct 2020) and by the Local Ethical Committee of Priorov CITO (№1/21 dated 25 Feb 2021). Preliminary and final results will be presented in peer-reviewed journals, at national and international congresses.
Trial registration number NCT04600544
STRENGTHS AND LIMITATIONS OF THIS STUDY
Two-center and multiple-discipline study: the study includes two centers (Moscow in the European and Novosibirsk in the Asian part of Russia), with research teams specializing in following fields: (1) clinical aspects of lumbar disc degeneration disease, (2) biology and genetics of pain, (3) generation of omics data and (4) multi-omics data analysis
Collection of variable biological material: whole blood, plasma and, for part of the participants, intraoperative material of the lumbar disc (with different DD status) will be available for omics studies
Objective diagnosis: lumbar DD status is confirmed by MRI, not self-reported diagnosis
Sample size is limited compared to nationwide biobanks
Patients with severe lumbar DD status will be more prevalent in the biobank than these with mild or no lumbar DD compared to the general population
Competing Interest Statement
YSA is a co-owner of Maatschap PolyOmica and PolyKnomics BV, private organizations, providing services, research and development in the field of quantitative and computational genomics.
Clinical Trial
NCT04600544
Funding Statement
The work of YAT and EEE was supported by the Russian Foundation for Basic Research (project 19-015-00151) and by the Ministry of Education and Science of the RF via the Institute of Cytology and Genetics SB RAS (project number 0259-2021-0009 / AAAA-A17-117092070032-4). The work of ONL and YSA was supported by the Russian Ministry of Science and Education under the 5-100 Excellence Programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study will be performed according to the Helsinki Declaration; the ethical approval was given by the Local Ethical Committee of Novosibirsk Research Institute of Traumatology and Orthopaedics n.a.Ya.L.Tsivyan ((№034/20 dated 02 Oct 2020) and by the Local Ethical Committee of Priorov National Medical Research Center of Traumatology and Orthopedics ((№1/21 dated 25 Feb 2021).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
To access the database, omcis data and other relevant information, projects should be submitted to the steering committee (contact the corresponding author) of the RuDDS.
